Authors:
ZENT CS
WILSON CS
TRICOT G
JAGANNATH S
SIEGEL D
DESIKAN KR
MUNSHI N
BRACY D
BARLOGIE B
BUTCH AW
Citation: Cs. Zent et al., OLIGOCLONAL PROTEIN BANDS AND IG ISOTYPE SWITCHING IN MULTIPLE-MYELOMA TREATED WITH HIGH-DOSE THERAPY AND HEMATOPOIETIC-CELL TRANSPLANTATION, Blood, 91(9), 1998, pp. 3518-3523
Authors:
ZENT CS
MATHIEU C
CLAXTON DF
ZHANG DE
TENEN DG
ROWLEY JD
NUCIFORA G
Citation: Cs. Zent et al., THE CHIMERIC GENES AML1 MDS1 AND AML1/EAP INHIBIT AML1B ACTIVATION ATTHE CSF1R PROMOTER, BUT ONLY AML1/MDS1 HAS TUMOR-PROMOTER PROPERTIES/, Proceedings of the National Academy of Sciences of the United Statesof America, 93(3), 1996, pp. 1044-1048
Authors:
ZENT CS
MATHIEU C
CLAXTON DF
ROWLEY JD
NUCIFORA G
Citation: Cs. Zent et al., AML1 MDS1 AND AML1/EAP BIND SPECIFICALLY TO AN AML1 DNA-BINDING SITE AND INHIBIT AML1B TRANSACTIVATION OF THE CSFIR PROMOTER DESPITE OVEREXPRESSION OF CBFB/, Blood, 86(10), 1995, pp. 2376-2376
Authors:
ZENT CS
LEBEAU MM
DALY KM
ONG TS
LESTER EP
LARSON RA
Citation: Cs. Zent et al., CLONAL EVOLUTION OF INV(16)(P13Q22) IN 2 PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN BLAST PHASE, Clinical research, 42(3), 1994, pp. 10000376-10000376
Citation: Cs. Zent et al., PREDICTION OF AMIKACIN DOSE REQUIREMENTS IN NEUTROPENIC PATIENTS WITHHEMATOLOGICAL DISEASE, South African medical journal, 83(11), 1993, pp. 853-854